Evaluation of the Impact of Electronic Monitoring on Patient Compliance in Hematology

Management of hemopathies has progressed with the arrival of new drugs such as CAR T-cells (Chimeric Antigen Receptor T-cells), immunotherapy and targeted therapies, while increasing emphasis is being placed on outpatient care. The emergence of oral therapies has simplified the treatment pathway, but they are not without their undesirable effects, which can sometimes lead to treatment suspension or even discontinuation. These undesirable effects may be related either to the haemopathy (pain, general signs, fatigue, malnutrition, infection, etc.), or to the toxicity of the treatments, or to co-morbidities. It is therefore essential to detect and manage these adverse effects in real time. In patients treated with oral therapy, poor compliance (\

Inclusion Criteria: * Follow-up for haemopathy justifying initiation of oral therapy (one or more authorized molecules) for more than 6 months (1st line of treatment or more), * Intravenous treatment may be associated with it, in accordance with international recommendations (immunotherapy, corticosteroid therapy, other), * Patient affiliated to a social security scheme, * Patient having given written consent prior to any specific study procedure. Exclusion Criteria: * Oral treatment expected to last \< 6 months, * Cerebral tumor involvement, * Other active cancer \< 3 years, excluding skin, prostate and cervical carcinomas treated by surgery alone, * Pregnancy or breast-feeding * Persons deprived of their liberty, under guardianship or curatorship, * Dementia, mental alteration or psychiatric pathology that could compromise the patient's informed consent and/or compliance with the protocol and trial follow-up, * Patient unable to undergo protocol monitoring for psychological, social, family or geographical reasons. * No Internet connection * No telephone line